Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?

Abstract

Objective

To compare survival of ovarian cancer patients treated with neoadjuvant chemotherapy followed by intraperitoneal (IP) versus intravenous (IV) chemotherapy after optimal interval debulking.

Conclusions

Survival benefit associated with IP chemotherapy after optimal upfront surgery may not translate to the neoadjuvant setting.

Research Highlights

► Macroscopic residual disease is associated with worse prognosis.
► No difference observed in complete response between IP and IV treated patients.
► IP chemotherapy benefits may not translate to the neoadjuvant setting.

Continued Uncertainty Regarding Hyperthermic Intraperitoneal Chemotherapy in Malignant Peritoneal Mesothelioma -- Markman 28 (24): e418 -- Journal of Clinical Oncology

Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II

CONCLUSION:
Using intra-peritoneal Oxaliplatin associated with hyperthermia as consolidation therapy for advanced ovarian cancer results in a high risk of grade 3 morbidities with only a small benefit on survival

The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer -- Helm 14 (7): 683 -- The Oncologist